Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2008

TEST: Cryo-Cell and Saneron Sign Research Deal in Stem Cell Technology

  • C’elle menstrual stem cells will be used in preclinical models of CNS disorders.
    Cryo-Cell inked an R&D agreement with Saneron CCEL Therapeutics to develop regenerative therapies using Cryo-Cell’s C’elle menstrual stem cell technology. The partners will work on preclinical models for particular neurological diseases.
    Cryo-Cell will provide C’elle menstrual stem cells along with associated techniques. Saneron will contribute study materials and research methodology for potential therapeutic applications. The companies will jointly own any intellectual property resulting from this research.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »